Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.50 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796833 | 1.00 | EPHX2 (0.53) | EPHX2SRD5A1SCD5RIPK1USP30 | |
| SCHEMBL796858 | 1.00 | EPHX2 (0.53) | EPHX2SRD5A1SCD5RIPK1USP30 | |
| SCHEMBL5271411 | 0.90 | EPHX2 (0.59) | EPHX2SRD5A1SCD5CYP2C9CYP2J2 | |
| SCHEMBL594896 | 0.87 | SRD5A1 (0.45) | EPHX2SRD5A1USP30 | |
| SCHEMBL6123598 | 0.87 | EPHX2 (0.51) | EPHX2SRD5A1SCD5RIPK1USP30 | |
| SCHEMBL10606119 | 0.87 | EPHX2 (0.54) | EPHX2SRD5A1SCD5RIPK1USP30 | |
| SCHEMBL594897 | 0.87 | SRD5A1 (0.45) | EPHX2SRD5A1USP30 | |
| SCHEMBL12442639 | 0.86 | NAMPT (0.57) | EPHX2SRD5A1SCD5RIPK1 | |
| SCHEMBL29067466 | 0.86 | POLB (0.47) | EPHX2SRD5A1GAACYP2C9 | |
| SCHEMBL29132289 | 0.86 | EPHX2 (0.54) | EPHX2CYP2C9CYP2J2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415350-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | claimed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| EP-4278014-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022152822-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| EP-3883925-A1 | CYCLIC UREAS | Sironax Ltd (KY) | 2021-09-29 | — | — | EP | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-9321769-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2015-08-20 | — | — | US | disclosed |
| US-9051321-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2015-06-09 | — | — | US | disclosed |
| US-20140357617-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2014-12-04 | — | — | US | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | EPHX2 1711/4885SRD5A1 128/4885SCD5 3709/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | EPHX2 1711/4885SRD5A1 128/4885SCD5 3709/4885 |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | EPHX2 1765/4885SRD5A1 2533/4885SCD5 3219/4885 |
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | EPHX2 2221/4885SRD5A1 3871/4885SCD5 4489/4885 |
| US-20140357617-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | EPHX2 2221/4885SRD5A1 3871/4885SCD5 4489/4885 |
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | EPHX2 3955/4885SRD5A1 2568/4885SCD5 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.